Baudax Bio (BXRX) Files Chapter 11

On February 22, 2024, Baudax Bio (NASDAQ: BXRX) filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy code (the “Bankruptcy Code”) in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania (the “Bankruptcy Court”) (the “Chapter 11 Case”). The Chapter 11 Case was assigned case number 2:24-bk-10583. The Company intends to continue operating its business during the Chapter 11 Case as a debtor-in-possession in accordance with the Bankruptcy Code and orders of the Bankruptcy Court.

You May Also Be Interested In

• Uniti Group prices $1.14 billion fiber network securitization offering
• Columbus McKinnon reports 20% order growth, 24% net sales increase in FY26
• Medallion Financial responds to ZimCal proxy contest allegations